BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VAS-101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VAS-101\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07566494-10339@assetmemo.bio
DTSTAMP:20261121T004021Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:VAS-101: Phase 1 readout est. (NCT07566494)
DESCRIPTION:VAS-101\, phase 1\, Sickle Cell Disease.\nStudy: Escalating Dos
 es of VAS-101 in Subjects With Stable Sickle Cell Disease\nEstimated prima
 ry completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/vas-101#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07566494
URL:https://assetmemo.bio/drug/vas-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
